GROWTH-FACTORS AND DIABETIC COMPLICATIONS

[31] Gerich JE, Loranzi M., Schneider V., Et al., Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus, N Engl J Med, 291, pp. 544-547, (1974)

[32] Plewe G., Noelken G., Krause U., Beyer J., del Pozo E., Suppression of growth hormone and somatomedin C by longacting somatostatin analogue SMS 201–995 in type 1 diabetes mellitus, Horm Res, 27, pp. 7-12, (1987)

[33] Grossman LD, Shumak SL, George SR, Singer W., Zinman B., The effects of SMS 201–995 (Sandostatin) on metabolic profiles in insulin‐dependent diabetes mellitus, J Clin Endocrinol Metab, 68, pp. 63-67, (1989)

[34] Spinas GA, Bock A., Keller U., Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin analogue (SMS 201–995) in insulin‐dependent diabetes mellitus, Diabetes Care, 8, pp. 429-435, (1985)

[35] Rios, Navascues I., Saban J., Ordonez A., Sevilla F., del Pozo E., Somatostatin analogue SMS 201–995 and insulin needs in insulin‐dependent diabetic patients studied by means of an artificial pancreas, J Clin Endocrinol Metab, 63, pp. 1071-1074, (1986)

[36] Osei K., O'Dorisio TM, Malarkey B., Craig EL, Cataland S., Metabolic effects of long‐acting somatostatin analogue (Sandostatin) in type 1 diabetic patients on conventional therapy, Diabetes, 38, pp. 704-709, (1989)

[37] Rios, Navascues I., Gil J., Seren D., Paseau C., Dawn phenomenon: Suppression by single nightly dose of somatostatin analogue SMS 201–995 (Abstract), Diabetes, 36, (1987)

[38] Willms B., Harris A., Mehmke B., Effects of a single nocturnal administration of a long‐acting somatostatin analogue, SMS 201–995 on blood glucose profile during the night, human growth hormone and cortisol secretion in Type 1 diabetic patients (Abstract), Diabetes, 30, (1987)

[39] Kohner EM, Sharp PS, Diabetic retinopathy, The Diabetes Annual/3, pp. 252-288, (1987)

[40] Christensen SE, Hansen, Weeke J., Lundbaek K., 24‐hour studies of the effect of somatostatin on the levels of plasma growth hormone and glucose in normal subjects and juvenile diabetics, Diabetes, 27, pp. 300-306, (1978)

[31] Gerich JE, Loranzi M., Schneider V., Et al., Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus, N Engl J Med, 291, pp. 544-547, (1974)

[32] Plewe G., Noelken G., Krause U., Beyer J., del Pozo E., Suppression of growth hormone and somatomedin C by longacting somatostatin analogue SMS 201–995 in type 1 diabetes mellitus, Horm Res, 27, pp. 7-12, (1987)

[33] Grossman LD, Shumak SL, George SR, Singer W., Zinman B., The effects of SMS 201–995 (Sandostatin) on metabolic profiles in insulin‐dependent diabetes mellitus, J Clin Endocrinol Metab, 68, pp. 63-67, (1989)

[34] Spinas GA, Bock A., Keller U., Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin analogue (SMS 201–995) in insulin‐dependent diabetes mellitus, Diabetes Care, 8, pp. 429-435, (1985)

[35] Rios, Navascues I., Saban J., Ordonez A., Sevilla F., del Pozo E., Somatostatin analogue SMS 201–995 and insulin needs in insulin‐dependent diabetic patients studied by means of an artificial pancreas, J Clin Endocrinol Metab, 63, pp. 1071-1074, (1986)

[36] Osei K., O'Dorisio TM, Malarkey B., Craig EL, Cataland S., Metabolic effects of long‐acting somatostatin analogue (Sandostatin) in type 1 diabetic patients on conventional therapy, Diabetes, 38, pp. 704-709, (1989)

[37] Rios, Navascues I., Gil J., Seren D., Paseau C., Dawn phenomenon: Suppression by single nightly dose of somatostatin analogue SMS 201–995 (Abstract), Diabetes, 36, (1987)

[38] Willms B., Harris A., Mehmke B., Effects of a single nocturnal administration of a long‐acting somatostatin analogue, SMS 201–995 on blood glucose profile during the night, human growth hormone and cortisol secretion in Type 1 diabetic patients (Abstract), Diabetes, 30, (1987)

[39] Kohner EM, Sharp PS, Diabetic retinopathy, The Diabetes Annual/3, pp. 252-288, (1987)

[40] Christensen SE, Hansen, Weeke J., Lundbaek K., 24‐hour studies of the effect of somatostatin on the levels of plasma growth hormone and glucose in normal subjects and juvenile diabetics, Diabetes, 27, pp. 300-306, (1978)